Global Meningococcal Vaccine Market Size, Manufacturers, Growth Analysis Industry Forecast to 2030

Global Meningococcal Vaccine Market Size, Manufacturers, Growth Analysis Industry Forecast to 2030


Summary

Meningococcal vaccine refers to any of the vaccines used to prevent infection by Neisseria meningitides. The vaccines are between 85 and 100% effective for at least two years. They result in a decrease in meningitis and sepsis among populations where they are widely used. They are given either by injection into a muscle or just under the skin.

According to APO Research, The global Meningococcal Vaccine market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

North American market for Meningococcal Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Asia-Pacific market for Meningococcal Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The China market for Meningococcal Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Europe market for Meningococcal Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The major global manufacturers of Meningococcal Vaccine include Novartis, GSK, Merck, CSL, Baxter, JN International Medical Corporation, Serum Institute of India, Bio-Med and China National Biotec Group, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Meningococcal Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.

This report researches the key producers of Meningococcal Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for Meningococcal Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Meningococcal Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Meningococcal Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Meningococcal Vaccine sales, projected growth trends, production technology, application and end-user industry.

Meningococcal Vaccine segment by Company

Novartis
GSK
Merck
CSL
Baxter
JN International Medical Corporation
Serum Institute of India
Bio-Med
China National Biotec Group
Hualan Bio
Walvax
Zhifei
Meningococcal Vaccine segment by Type

Meningtits A
Polysaccharide Meningtitis AC
Meningitis ACYW
Meningococcal Vaccine segment by Application

6 Months-15Year
over 3 Year
over 2 Year
over 3 Months
Meningococcal Vaccine segment by Region

North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global Meningococcal Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Meningococcal Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Meningococcal Vaccine significant trends, drivers, influence factors in global and regions.
6. To analyze Meningococcal Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Meningococcal Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Meningococcal Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Meningococcal Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Meningococcal Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2019-2030).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Meningococcal Vaccine industry.
Chapter 3: Detailed analysis of Meningococcal Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Meningococcal Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Meningococcal Vaccine in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.


1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Meningococcal Vaccine Sales Value (2019-2030)
1.2.2 Global Meningococcal Vaccine Sales Volume (2019-2030)
1.2.3 Global Meningococcal Vaccine Sales Average Price (2019-2030)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Meningococcal Vaccine Market Dynamics
2.1 Meningococcal Vaccine Industry Trends
2.2 Meningococcal Vaccine Industry Drivers
2.3 Meningococcal Vaccine Industry Opportunities and Challenges
2.4 Meningococcal Vaccine Industry Restraints
3 Meningococcal Vaccine Market by Company
3.1 Global Meningococcal Vaccine Company Revenue Ranking in 2023
3.2 Global Meningococcal Vaccine Revenue by Company (2019-2024)
3.3 Global Meningococcal Vaccine Sales Volume by Company (2019-2024)
3.4 Global Meningococcal Vaccine Average Price by Company (2019-2024)
3.5 Global Meningococcal Vaccine Company Ranking, 2022 VS 2023 VS 2024
3.6 Global Meningococcal Vaccine Company Manufacturing Base & Headquarters
3.7 Global Meningococcal Vaccine Company, Product Type & Application
3.8 Global Meningococcal Vaccine Company Commercialization Time
3.9 Market Competitive Analysis
3.9.1 Global Meningococcal Vaccine Market CR5 and HHI
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2023
3.9.3 2023 Meningococcal Vaccine Tier 1, Tier 2, and Tier
3.10 Mergers & Acquisitions, Expansion
4 Meningococcal Vaccine Market by Type
4.1 Meningococcal Vaccine Type Introduction
4.1.1 Meningtits A
4.1.2 Polysaccharide Meningtitis AC
4.1.3 Meningitis ACYW
4.2 Global Meningococcal Vaccine Sales Volume by Type
4.2.1 Global Meningococcal Vaccine Sales Volume by Type (2019 VS 2023 VS 2030)
4.2.2 Global Meningococcal Vaccine Sales Volume by Type (2019-2030)
4.2.3 Global Meningococcal Vaccine Sales Volume Share by Type (2019-2030)
4.3 Global Meningococcal Vaccine Sales Value by Type
4.3.1 Global Meningococcal Vaccine Sales Value by Type (2019 VS 2023 VS 2030)
4.3.2 Global Meningococcal Vaccine Sales Value by Type (2019-2030)
4.3.3 Global Meningococcal Vaccine Sales Value Share by Type (2019-2030)
5 Meningococcal Vaccine Market by Application
5.1 Meningococcal Vaccine Application Introduction
5.1.1 6 Months-15Year
5.1.2 over 3 Year
5.1.3 over 2 Year
5.1.4 over 3 Months
5.2 Global Meningococcal Vaccine Sales Volume by Application
5.2.1 Global Meningococcal Vaccine Sales Volume by Application (2019 VS 2023 VS 2030)
5.2.2 Global Meningococcal Vaccine Sales Volume by Application (2019-2030)
5.2.3 Global Meningococcal Vaccine Sales Volume Share by Application (2019-2030)
5.3 Global Meningococcal Vaccine Sales Value by Application
5.3.1 Global Meningococcal Vaccine Sales Value by Application (2019 VS 2023 VS 2030)
5.3.2 Global Meningococcal Vaccine Sales Value by Application (2019-2030)
5.3.3 Global Meningococcal Vaccine Sales Value Share by Application (2019-2030)
6 Meningococcal Vaccine Market by Region
6.1 Global Meningococcal Vaccine Sales by Region: 2019 VS 2023 VS 2030
6.2 Global Meningococcal Vaccine Sales by Region (2019-2030)
6.2.1 Global Meningococcal Vaccine Sales by Region: 2019-2024
6.2.2 Global Meningococcal Vaccine Sales by Region (2025-2030)
6.3 Global Meningococcal Vaccine Sales Value by Region: 2019 VS 2023 VS 2030
6.4 Global Meningococcal Vaccine Sales Value by Region (2019-2030)
6.4.1 Global Meningococcal Vaccine Sales Value by Region: 2019-2024
6.4.2 Global Meningococcal Vaccine Sales Value by Region (2025-2030)
6.5 Global Meningococcal Vaccine Market Price Analysis by Region (2019-2024)
6.6 North America
6.6.1 North America Meningococcal Vaccine Sales Value (2019-2030)
6.6.2 North America Meningococcal Vaccine Sales Value Share by Country, 2023 VS 2030
6.7 Europe
6.7.1 Europe Meningococcal Vaccine Sales Value (2019-2030)
6.7.2 Europe Meningococcal Vaccine Sales Value Share by Country, 2023 VS 2030
6.8 Asia-Pacific
6.8.1 Asia-Pacific Meningococcal Vaccine Sales Value (2019-2030)
6.8.2 Asia-Pacific Meningococcal Vaccine Sales Value Share by Country, 2023 VS 2030
6.9 Latin America
6.9.1 Latin America Meningococcal Vaccine Sales Value (2019-2030)
6.9.2 Latin America Meningococcal Vaccine Sales Value Share by Country, 2023 VS 2030
6.10 Middle East & Africa
6.10.1 Middle East & Africa Meningococcal Vaccine Sales Value (2019-2030)
6.10.2 Middle East & Africa Meningococcal Vaccine Sales Value Share by Country, 2023 VS 2030
7 Meningococcal Vaccine Market by Country
7.1 Global Meningococcal Vaccine Sales by Country: 2019 VS 2023 VS 2030
7.2 Global Meningococcal Vaccine Sales Value by Country: 2019 VS 2023 VS 2030
7.3 Global Meningococcal Vaccine Sales by Country (2019-2030)
7.3.1 Global Meningococcal Vaccine Sales by Country (2019-2024)
7.3.2 Global Meningococcal Vaccine Sales by Country (2025-2030)
7.4 Global Meningococcal Vaccine Sales Value by Country (2019-2030)
7.4.1 Global Meningococcal Vaccine Sales Value by Country (2019-2024)
7.4.2 Global Meningococcal Vaccine Sales Value by Country (2025-2030)
7.5 USA
7.5.1 Global Meningococcal Vaccine Sales Value Growth Rate (2019-2030)
7.5.2 Global Meningococcal Vaccine Sales Value Share by Type, 2023 VS 2030
7.5.3 Global Meningococcal Vaccine Sales Value Share by Application, 2023 VS 2030
7.6 Canada
7.6.1 Global Meningococcal Vaccine Sales Value Growth Rate (2019-2030)
7.6.2 Global Meningococcal Vaccine Sales Value Share by Type, 2023 VS 2030
7.6.3 Global Meningococcal Vaccine Sales Value Share by Application, 2023 VS 2030
7.7 Germany
7.7.1 Global Meningococcal Vaccine Sales Value Growth Rate (2019-2030)
7.7.2 Global Meningococcal Vaccine Sales Value Share by Type, 2023 VS 2030
7.7.3 Global Meningococcal Vaccine Sales Value Share by Application, 2023 VS 2030
7.8 France
7.8.1 Global Meningococcal Vaccine Sales Value Growth Rate (2019-2030)
7.8.2 Global Meningococcal Vaccine Sales Value Share by Type, 2023 VS 2030
7.8.3 Global Meningococcal Vaccine Sales Value Share by Application, 2023 VS 2030
7.9 U.K.
7.9.1 Global Meningococcal Vaccine Sales Value Growth Rate (2019-2030)
7.9.2 Global Meningococcal Vaccine Sales Value Share by Type, 2023 VS 2030
7.9.3 Global Meningococcal Vaccine Sales Value Share by Application, 2023 VS 2030
7.10 Italy
7.10.1 Global Meningococcal Vaccine Sales Value Growth Rate (2019-2030)
7.10.2 Global Meningococcal Vaccine Sales Value Share by Type, 2023 VS 2030
7.10.3 Global Meningococcal Vaccine Sales Value Share by Application, 2023 VS 2030
7.11 Netherlands
7.11.1 Global Meningococcal Vaccine Sales Value Growth Rate (2019-2030)
7.11.2 Global Meningococcal Vaccine Sales Value Share by Type, 2023 VS 2030
7.11.3 Global Meningococcal Vaccine Sales Value Share by Application, 2023 VS 2030
7.12 Nordic Countries
7.12.1 Global Meningococcal Vaccine Sales Value Growth Rate (2019-2030)
7.12.2 Global Meningococcal Vaccine Sales Value Share by Type, 2023 VS 2030
7.12.3 Global Meningococcal Vaccine Sales Value Share by Application, 2023 VS 2030
7.13 China
7.13.1 Global Meningococcal Vaccine Sales Value Growth Rate (2019-2030)
7.13.2 Global Meningococcal Vaccine Sales Value Share by Type, 2023 VS 2030
7.13.3 Global Meningococcal Vaccine Sales Value Share by Application, 2023 VS 2030
7.14 Japan
7.14.1 Global Meningococcal Vaccine Sales Value Growth Rate (2019-2030)
7.14.2 Global Meningococcal Vaccine Sales Value Share by Type, 2023 VS 2030
7.14.3 Global Meningococcal Vaccine Sales Value Share by Application, 2023 VS 2030
7.15 South Korea
7.15.1 Global Meningococcal Vaccine Sales Value Growth Rate (2019-2030)
7.15.2 Global Meningococcal Vaccine Sales Value Share by Type, 2023 VS 2030
7.15.3 Global Meningococcal Vaccine Sales Value Share by Application, 2023 VS 2030
7.16 Southeast Asia
7.16.1 Global Meningococcal Vaccine Sales Value Growth Rate (2019-2030)
7.16.2 Global Meningococcal Vaccine Sales Value Share by Type, 2023 VS 2030
7.16.3 Global Meningococcal Vaccine Sales Value Share by Application, 2023 VS 2030
7.17 India
7.17.1 Global Meningococcal Vaccine Sales Value Growth Rate (2019-2030)
7.17.2 Global Meningococcal Vaccine Sales Value Share by Type, 2023 VS 2030
7.17.3 Global Meningococcal Vaccine Sales Value Share by Application, 2023 VS 2030
7.18 Australia
7.18.1 Global Meningococcal Vaccine Sales Value Growth Rate (2019-2030)
7.18.2 Global Meningococcal Vaccine Sales Value Share by Type, 2023 VS 2030
7.18.3 Global Meningococcal Vaccine Sales Value Share by Application, 2023 VS 2030
7.19 Mexico
7.19.1 Global Meningococcal Vaccine Sales Value Growth Rate (2019-2030)
7.19.2 Global Meningococcal Vaccine Sales Value Share by Type, 2023 VS 2030
7.19.3 Global Meningococcal Vaccine Sales Value Share by Application, 2023 VS 2030
7.20 Brazil
7.20.1 Global Meningococcal Vaccine Sales Value Growth Rate (2019-2030)
7.20.2 Global Meningococcal Vaccine Sales Value Share by Type, 2023 VS 2030
7.20.3 Global Meningococcal Vaccine Sales Value Share by Application, 2023 VS 2030
7.21 Turkey
7.21.1 Global Meningococcal Vaccine Sales Value Growth Rate (2019-2030)
7.21.2 Global Meningococcal Vaccine Sales Value Share by Type, 2023 VS 2030
7.21.3 Global Meningococcal Vaccine Sales Value Share by Application, 2023 VS 2030
7.22 Saudi Arabia
7.22.1 Global Meningococcal Vaccine Sales Value Growth Rate (2019-2030)
7.22.2 Global Meningococcal Vaccine Sales Value Share by Type, 2023 VS 2030
7.22.3 Global Meningococcal Vaccine Sales Value Share by Application, 2023 VS 2030
7.23 UAE
7.23.1 Global Meningococcal Vaccine Sales Value Growth Rate (2019-2030)
7.23.2 Global Meningococcal Vaccine Sales Value Share by Type, 2023 VS 2030
7.23.3 Global Meningococcal Vaccine Sales Value Share by Application, 2023 VS 2030
8 Company Profiles
8.1 Novartis
8.1.1 Novartis Comapny Information
8.1.2 Novartis Business Overview
8.1.3 Novartis Meningococcal Vaccine Sales, Value and Gross Margin (2019-2024)
8.1.4 Novartis Meningococcal Vaccine Product Portfolio
8.1.5 Novartis Recent Developments
8.2 GSK
8.2.1 GSK Comapny Information
8.2.2 GSK Business Overview
8.2.3 GSK Meningococcal Vaccine Sales, Value and Gross Margin (2019-2024)
8.2.4 GSK Meningococcal Vaccine Product Portfolio
8.2.5 GSK Recent Developments
8.3 Merck
8.3.1 Merck Comapny Information
8.3.2 Merck Business Overview
8.3.3 Merck Meningococcal Vaccine Sales, Value and Gross Margin (2019-2024)
8.3.4 Merck Meningococcal Vaccine Product Portfolio
8.3.5 Merck Recent Developments
8.4 CSL
8.4.1 CSL Comapny Information
8.4.2 CSL Business Overview
8.4.3 CSL Meningococcal Vaccine Sales, Value and Gross Margin (2019-2024)
8.4.4 CSL Meningococcal Vaccine Product Portfolio
8.4.5 CSL Recent Developments
8.5 Baxter
8.5.1 Baxter Comapny Information
8.5.2 Baxter Business Overview
8.5.3 Baxter Meningococcal Vaccine Sales, Value and Gross Margin (2019-2024)
8.5.4 Baxter Meningococcal Vaccine Product Portfolio
8.5.5 Baxter Recent Developments
8.6 JN International Medical Corporation
8.6.1 JN International Medical Corporation Comapny Information
8.6.2 JN International Medical Corporation Business Overview
8.6.3 JN International Medical Corporation Meningococcal Vaccine Sales, Value and Gross Margin (2019-2024)
8.6.4 JN International Medical Corporation Meningococcal Vaccine Product Portfolio
8.6.5 JN International Medical Corporation Recent Developments
8.7 Serum Institute of India
8.7.1 Serum Institute of India Comapny Information
8.7.2 Serum Institute of India Business Overview
8.7.3 Serum Institute of India Meningococcal Vaccine Sales, Value and Gross Margin (2019-2024)
8.7.4 Serum Institute of India Meningococcal Vaccine Product Portfolio
8.7.5 Serum Institute of India Recent Developments
8.8 Bio-Med
8.8.1 Bio-Med Comapny Information
8.8.2 Bio-Med Business Overview
8.8.3 Bio-Med Meningococcal Vaccine Sales, Value and Gross Margin (2019-2024)
8.8.4 Bio-Med Meningococcal Vaccine Product Portfolio
8.8.5 Bio-Med Recent Developments
8.9 China National Biotec Group
8.9.1 China National Biotec Group Comapny Information
8.9.2 China National Biotec Group Business Overview
8.9.3 China National Biotec Group Meningococcal Vaccine Sales, Value and Gross Margin (2019-2024)
8.9.4 China National Biotec Group Meningococcal Vaccine Product Portfolio
8.9.5 China National Biotec Group Recent Developments
8.10 Hualan Bio
8.10.1 Hualan Bio Comapny Information
8.10.2 Hualan Bio Business Overview
8.10.3 Hualan Bio Meningococcal Vaccine Sales, Value and Gross Margin (2019-2024)
8.10.4 Hualan Bio Meningococcal Vaccine Product Portfolio
8.10.5 Hualan Bio Recent Developments
8.11 Walvax
8.11.1 Walvax Comapny Information
8.11.2 Walvax Business Overview
8.11.3 Walvax Meningococcal Vaccine Sales, Value and Gross Margin (2019-2024)
8.11.4 Walvax Meningococcal Vaccine Product Portfolio
8.11.5 Walvax Recent Developments
8.12 Zhifei
8.12.1 Zhifei Comapny Information
8.12.2 Zhifei Business Overview
8.12.3 Zhifei Meningococcal Vaccine Sales, Value and Gross Margin (2019-2024)
8.12.4 Zhifei Meningococcal Vaccine Product Portfolio
8.12.5 Zhifei Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Meningococcal Vaccine Value Chain Analysis
9.1.1 Meningococcal Vaccine Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Meningococcal Vaccine Sales Mode & Process
9.2 Meningococcal Vaccine Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Meningococcal Vaccine Distributors
9.2.3 Meningococcal Vaccine Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings